The diagnostics and treatment of gynecologic malignancies have changed profoundly in recent years due to the achievements of modern molecular pathology. The further development of sequencing techniques and other molecular pathology methods, such as liquid biopsy, homologous recombination deficiency (HRD) testing, and multigene testing have led to the identification of numerous prognostic and predictive biomarkers and resistance markers in breast, ovarian, and endometrial cancers. In parallel with the identification of novel oncogenic drivers and therapeutic targets, numerous innovative targeted therapies have been introduced into routine clinical practice. This article highlights the groundbreaking new molecular pathology findings in gynecologic oncology in the temporal context of the past 20 years and describes a revolution that has occurred in modern precision targeted oncology.     «

The diagnostics and treatment of gynecologic malignancies have changed profoundly in recent years due to the achievements of modern molecular pathology. The further development of sequencing techniques and other molecular pathology methods, such as liquid biopsy, homologous recombination deficiency (HRD) testing, and multigene testing have led to the identification of numerous prognostic and predictive biomarkers and resistance markers in breast, ovarian, and endometrial cancers. In parallel wit...     »